AI주식인사이트AI Stock Insight
B

HLB파나진

046210KOSDAQ

56.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 18.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Panajin is a specialized biotech venture company focusing on PNA (Peptide Nucleic Acid)-based bio materials and molecular diagnostics. The company develops and commercializes diverse diagnostic products, including somatic mutation detection, liquid biopsy, and automated diagnostic technologies, leveraging its PNA platform. Its subsidiary, BioSquare, expands into immunoassay technologies, while the company aims to build an AI-based diagnostic platform and develop PNA-based therapeutics for comprehensive healthcare solutions.

Number of Employees

84people

Average Salary

51.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.87Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-4.21Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
2.48Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -5.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 1,389Won52-week high 2,65052-week low 999
1-month return6.0Point

1m +18.41% (strong rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기업설명회(IR)개최2026-10-12